A versatile drug delivery system using streptavidin-tagged pegylated liposomes and biotinylated biomaterials

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 478-485

  Chen, Ming Han ^a   Soda, Yasushi ^b   Izawa, Kiyoko ^c   Kobayashi, Seiichiro ^c   Tani, Kenzaburo ^d   Maruyama, Kazuo ^e   Tojo, Arinobu ^c   Asano, Shigetaka ^f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

^f WASEDA UNIVERSITY   (Japan)

Author keywords

Biotin; Drug delivery system; Immunoliposome; Internalization; Streptavidin; Tumor targeting

Indexed keywords

BIOMATERIAL; BIOTIN; CALCEIN; CD33 ANTIGEN; CD7 ANTIGEN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; STREPTAVIDIN;

ANIMAL CELL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 84884151378     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.031     Document Type: Article

References (36)

1. Ahmad, I., Longenecker, M., Samuel, J., Allen, T.M., 1993. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53, 1484-1488. (Pubitemid 23113215)
2. Allen, T.M., 1997. Liposomes. Opportunities in drug delivery. Drugs 54, 8-14. (Pubitemid 27487790)
3. Allen, T.M., 2002. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763. (Pubitemid 37328910)
4. Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., Kamada, N., 1991. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77, 2031-2036.
5. Awasthi, V., Goins, B., Klipper, R., Loredo, R., Korvick, D., Phillips, W.T., 1998. Imaging experimental osteomyelitis using radiolabeled liposomes. J. Nucl. Med. 39, 1089-1094. (Pubitemid 28270133)
6. Diamandis, E.P., Christopoulos, T.K., 1991. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin. Chem. 37, 625-636. (Pubitemid 21892699)
7. Drexler, H.G., Matsuo, A.Y., MacLeod, R.A., 2000. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk. Res. 24, 881-911.
8. Drexler, H.G., Minowada, J., 1998. History and classification of human leukemialymphoma cell lines. Leuk. Lymphoma 31, 305-316. (Pubitemid 29033951)
9. Eliaz, R.E., Szoka Jr., F.C., 2001. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61, 2592-2601. (Pubitemid 32685844)
10. Forraz, N., Pettengell, R., McGuckin, C.P., 2004. Characterization of a lineage-negative stem-progenitor cell population optimized for ex vivo expansion and enriched for LTC-IC. Stem Cells 22, 100-108. (Pubitemid 38018786)
11. Haniu, M., Horan, T., Arakawa, T., Le, J., Katta, V., Hara, S., Rohde, M.F., 1996. Disulfide structure and N-glycosylation sites of an extracellular domain of granulocytecolony stimulating factor receptor. Biochemistry 35, 13040-13046. (Pubitemid 26349453)
12. Harata, M., Soda, Y., Tani, K., Ooi, J., Takizawa, T., Chen, M., Bai, Y., Izawa, K., Kobayashi, S., Tomonari, A., Nagamura, F., Takahashi, S., Uchimaru, K., Iseki, T., Tsuji, T., Takahashi, T.A., Sugita, K., Nakazawa, S., Tojo, A., Maruyama, K., Asano, S., 2004. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 104, 1442-1449. (Pubitemid 39166523)
13. Hertlein, E., Triantafillou, G., Sass, E.J., Hessler, J.D., Zhang, X., Jarjoura, D., Lucas, D.M., Muthusamy, N., Goldenberg, D.M., Lee, R.J., Byrd, J.C., 2010. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 116, 2554-2558.
14. Jiang, J., Yang, S.J., Wang, J.C., Yang, L.J., Xu, Z.Z., Yang, T., Liu, X.Y., Zhang, Q., 2013. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 76, 170-178.
15. Jung, L.K., Fu, S.M., 1989. A sandwich CD7-ELISA for detection of solubilized CD7 from normal and leukemic T cells. J. Immunol. Methods 116, 137-144. (Pubitemid 19028769)
16. Knox, S.J., Goris, M.L., Tempero, M., Weiden, P.L., Gentner, L., Breitz, H., Adams, G.P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D.R., Colcher, D., Horak, I.D., Weiner, L.M., 2000. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6, 406-414. (Pubitemid 30111457)
17. Lesch, H.P., Kaikkonen, M.U., Pikkarainen, J.T., Yla-Herttuala, S., 2010. Avidin-biotin technology in targeted therapy. Expert Opin. Drug Deliv. 7, 551-564.
18. Maruyama, K., 2002. PEG-immunoliposome. Biosci. Rep. 22, 251-266. (Pubitemid 35222734)
19. Maruyama, K., 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev. 63, 161-169.
20. Maruyama, K., Takizawa, T., Yuda, T., Kennel, S.J., Huang, L., Iwatsuru, M., 1995. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234, 74-80.
21. Minko, T., Dharap, S.S., Pakunlu, R.I., Wang, Y., 2004. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 5, 389-406. (Pubitemid 38559349)
22. Pan, X.Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., Lee, R.J., 2002. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100, 594-602. (Pubitemid 34761124)
23. Park, J.W., Hong, K., Kirpotin, D.B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U.B., Marks, J.D., Moore, D., Papahadjopoulos, D., Benz, C.C., 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181. (Pubitemid 35177372)
24. Pea, F., Russo, D., Michieli, M., Baraldo, M., Ermacora, A., Damiani, D., Baccarani, M., Furlanut, M., 2000. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemother. Pharmacol. 46, 279-286.
25. Preijers, F.W., Tax, W.J., De Witte, T., Janssen, A., vd Heijden, H., Vidal, H., Wessels, J.M., Capel, P.J., 1988. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins. Br. J. Haematol. 70, 289-294. (Pubitemid 18265246)
26. Rowlinson-Busza, G., Epenetos, A.A., 1992. Targeted delivery of biologic and other antineoplastic agents. Curr. Opin. Oncol. 4, 1142-1148.
27. Sadzuka, Y., 2000. Effective prodrug liposome and conversion to active metabolite. Curr. Drug Metab. 1, 31-48.
28. Sapra, P., Allen, T.M., 2003. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42, 439-462. (Pubitemid 36700404)
29. Setoyama, M., Tojo, A., Nagamura, F., Asano, S., Ishimae, M., Eguchi, M., Kamada, N., 1998. A unique translocation of the TEL gene in a case of acute myelogenous leukemia with inv(12)(p13q15). Blood 92, 1454-1455. (Pubitemid 28369061)
30. Simmons, D., Seed, B., 1988. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J. Immunol. 141, 2797-2800. (Pubitemid 18263070)
31. Stong, R.C., Uckun, F., Youle, R.J., Kersey, J.H., Vallera, D.A., 1985. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 66, 627-635. (Pubitemid 15230768)
32. Sugano, M., Egilmez, N.K., Yokota, S.J., Chen, F.A., Harding, J., Huang, S.K., Bankert, R.B., 2000. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 60, 6942-6949. (Pubitemid 32059167)
33. Tsuji, K., Ebihara, Y., 2001. Expression of G-CSF receptor on myeloid progenitors. Leuk. Lymphoma 42, 1351-1357. (Pubitemid 34082925)
34. van Der Velden, V.H., te Marvelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S., van Dongen, J.J., 2001. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97, 3197-3204.
35. Weiden, P.L., Breitz, H.B., Press, O., Appelbaum, J.W., Bryan, J.K., Gaffigan, S., Stone, D., Axworthy, D., Fisher, D., Reno, J., 2000. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother. Radiopharm. 15, 15-29. (Pubitemid 30108614)
36. Xu, L., Huang, C.C., Huang, W., Tang, W.H., Rait, A., Yin, Y.Z., Cruz, I., Xiang, L.M., Pirollo, K.F., Chang, E.H., 2002. Systemic tumor-targeted gene delivery by antitransferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337-346.